Position Summary:

Quotient is seeking a highly analytical and scientifically curious Senior Analyst to support strategic decision-making across our growing drug development pipeline. This is an exciting opportunity to work at the intersection of analytics, market intelligence, commercial strategy and early drug development in a genetics-based biotech company.

The successful candidate will combine strong analytical skills and familiarity with scientific and clinical data with commercial curiosity, to turn networks of complex data into meaningful insights. In doing so, the successful candidate will help us better understand where high-value, tractable drug development opportunities exist across our internal pipeline of drug targets, and more broadly across a range of disease areas. Together with other members of the drug development team, this role will help focus which indications, patient segments, and development paths we should consider, and where data can help inform our investment and planning decisions.

This role could be based in our UK or US office and will report to the Chief Development Officer.

Responsibilities:

• Across a range of disease/therapeutic areas, build a deep understanding of addressable markets, industry landscape, customer (health care practitioner, payor, and patient) needs, and forecast future states and opportunities for growth in sectors of interest
• Carry out market sizing, competitive analysis using epidemiology, clinical, and commercial data sets, and validate through research with external experts
• Partner with clinical, drug development and external experts/customers to further validate specific market segments and develop target product profiles (TPPs)
• Partner with Finance, Business development, and Drug Development teams to develop asset and disease area valuation models (e.g., rNPV) and support BD and finance discussions with valuation and commercial forecast models as required
• Design and improve data models, analytical frameworks, and output formats, that support assessments, presentation to stakeholders and internal decision-making
• Develop dashboards, reporting, and analysis tools to communicate outputs and disease area strategy. Develop and maintain revenue forecasts, pipeline models, and scenario analyses.
• Prototype, test, and help deploy AI-enabled tools, agents, and other analytical resources to support all the above analyses; working with end users and internal teams to refine successful solutions
• Provide insights to drug development, project management, and finance teams to support target-setting and internal development planning.

Qualifications:

Essential

• Bachelor's degree in health sciences discipline or a related field
• 3+ years of experience working in or with pharmaceutical or biotech companies (including via consulting firms) in product planning or commercial strategy teams
• Experience in at least one of these disease segments: Cardiovascular, renal, metabolic, oncology, autoimmune diseases
• Familiarity with drug development strategy and regulatory pathways
• Experience with a range of healthcare or life-sciences databases and market research tools
• Exposure to valuation, business development, licensing, or investment analysis
• Strong analytical and research skills
• Familiarity with and ability to synthesize scientific, medical, and economic data
• Strong business acumen and problem-solving capabilities
• Strong written and verbal communication skills
• Ability to work independently yet collaboratively, manage multiple projects, and meet deadlines

Desirable

• MD, PhD, or other advanced degree
• 4-6+ years of industry experience
• Knowledge of genomic-based approaches to drug target discovery

Values and Behaviors:

• Encourage respectful disagreement and cultivate open-minded, ego-free interactions to continuously push each other towards excellence
• Seek out diverse perspectives; practice active listening and genuine curiosity to ensure all contributions are valued, regardless of source
• Recognize the impact of your behavior, language and attitudes, and strive for balanced, meaningful exchanges that enhance mutual growth and understanding in all interactions
• Use a company-first mindset to guide decision-making; prioritize team over individual success
• Take calculated risks and challenge convention in the quest for exceptional outcomes

About Quotient:

Quotient Therapeutics is a privately-held, early stage company developing breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our work in somatic genomics, we are forging a new status quo for biopharma research and development across a broad pipeline of internal and partnered programs.

The company was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), and Syros Pharmaceuticals (SYRS).

Quotient Therapeutics and Flagship Pioneering are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

Recruitment & Staffing Agencies:

Quotient Therapeutics (“Quotient”) and Flagship Pioneering (“FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Quotient, FSP or their employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.